Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission
Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission
批准号:
8493991
负责人:
B. KIM LEE SIM
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-20 至 2015-05-31
关键词:
AdhesivesAdjuvantAfricaAntibodiesAntibody FormationAntigen TargetingAntigensAttenuatedBiologicalBiological AssayBiteBloodBusinessesCellsCessation of lifeChildClinicalClinical TrialsCulicidaeCyclic GMPDataDevelopmentDoseEndotoxinsEnzyme-Linked Immunosorbent AssayErythrocytesFemale AdolescentsFutureGoalsHepatocyteHigh Pressure Liquid ChromatographyImmune SeraImmunizationIn VitroInfantInfection preventionLife Cycle StagesLiverMalariaMalaria VaccinesMarketingMeasuresMembraneMidgutMilitary PersonnelMusN-terminalOocystsOutcomeParasitesPhasePichiaPlasmodium falciparumPregnancyPrevalenceProductionProteinsPublic HealthPublic SectorRadiationRecombinantsRegimenRodentSalivary GlandsSeriesSerumSporozoitesStagingStressStudy of serumT-LymphocyteTestingVaccine AntigenVaccinesVon Willebrand Factor A Domainbasecircumsporozoitecircumsporozoite proteindisease transmissionfeedingglobal healthimmunogenicityin vivoinnovationpreventresponsetransmission processvaccine candidatevaccine developmentvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We believe that eradication of malaria is achievable but not without a potent vaccine that interrupt malaria transmission (VIMT) transmission blocking vaccine. A logical and promising strategy is to combine target antigens from multiple stages to potently prevent transmission. To prevent transmission a vaccine should target the pre-erythrocytic (sporozoite and liver stages) and the sexual-mosquito stages of the life cycle. An ideal malaria vaccine would prevent infection, disease, and transmission by targeting at a minimum the pre- erythrocytic (sporozoites and liver stages) and optimally other stages of the parasite life cycle also. Pre- erythrocytic stage vaccine development is based on the observation that immunization via bites of irradiated mosquitoes infected with Plasmodium falciparum (Pf) sporozoites (SPZ) provides high-level protection. The circumsporozoite protein (CSP) was discovered by immunizing mice with irradiated SPZ. A higher percent of volunteers immunized with radiation attenuated PfSPZ have T cells that recognize Pf cell-traversal protein for ookinetes and sporozoites (PfCelTOS) than PfCSP, and immunization of mice with PfCelTOS protects against challenge with rodent malaria SPZ at the pre-erythrocytic stage. We have discovered that antibodies induced in mice by immunizing with recombinant (r) PfCelTOS with adjuvant inhibited Pf development to oocysts in mosquitoes in vivo and PfSPZ invasion and development in hepatocytes in vitro. When mice were immunized with rPfCelTOS alone, rPfCSP alone, or both, mice immunized with both proteins had higher Abs against PfSPZ and activity in blocking SPZ invasion and development in hepatocytes (86%) than did mice immunized with either protein individually. The observations that antibodies against rPfCelTOS, had biological activity against parasite mosquito (ookinete) and pre-erythrocytic (SPZ) stages, and were additive or synergistic with anti-PfCSP antibodies against SPZ are unique, and argue for further development of this protein. To further enhance VIMT effects, we will assess Pf von Willebrand factor A domain-related protein (PfWARP), a highly conserved, soluble ookinete specific protein that we have shown previously to potently inhibit development of oocysts in the mosquito midgut. Our aim in this study is to develop a combined multiple stage vaccine to potently prevent transmission by inhibition of oocyst development. PfCelTOS and PfCSP are also expressed in hemocoel stage sporozoites and thus our strategy would also target the conversion of oocysts to infectious sporozoites in the salivary glands. We will study the three proteins as immunogens alone and in combination, aiming to induce 100% transmission blocking activity. We believe that eradication of malaria is achievable but not without a potent transmission blocking vaccine, and that these 3 proteins can achieve this goal. Such a vaccine would be used in infants, young children, adolescent females (prevent malaria in pregnancy) and malaria elimination campaigns as a public health measure; an enormous global health market.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine
-
批准号:10547414
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:B. KIM LEE SIM
-
依托单位:
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine
-
批准号:10634703
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:B. KIM LEE SIM
-
依托单位:
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
-
批准号:10388090
-
项目类别:
-
资助金额:$127.92万
-
财政年份:2021
-
负责人:B. KIM LEE SIM
-
依托单位:
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
-
批准号:10598124
-
项目类别:
-
资助金额:$124.37万
-
财政年份:2021
-
负责人:B. KIM LEE SIM
-
依托单位:
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
-
批准号:10603814
-
项目类别:
-
资助金额:$99.99万
-
财政年份:2020
-
负责人:B. KIM LEE SIM
-
依托单位:
Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers
-
批准号:9202738
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2016
-
负责人:B. KIM LEE SIM
-
依托单位:
Live Attenuated Oral Typhoid-Shigellosis Vaccine
-
批准号:8903927
-
项目类别:
-
资助金额:$30.74万
-
财政年份:2015
-
负责人:B. KIM LEE SIM
-
依托单位:
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
-
批准号:8463454
-
项目类别:
-
资助金额:$106.31万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells
-
批准号:8251057
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
-
批准号:8653932
-
项目类别:
-
资助金额:$110.03万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Multi-ligand merozoite invasion blocking malaria vaccine
-
批准号:8490296
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Multi-ligand merozoite invasion blocking malaria vaccine
-
批准号:8251428
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
-
批准号:8269534
-
项目类别:
-
资助金额:$141.2万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells
-
批准号:8495921
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission
-
批准号:8315463
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:B. KIM LEE SIM
-
依托单位:
Live Attenuated Oral Anthrax Vaccine
-
批准号:8001640
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2010
-
负责人:B. KIM LEE SIM
-
依托单位:
Live Attenuated Oral Anthrax Vaccine
-
批准号:8101247
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2010
-
负责人:B. KIM LEE SIM
-
依托单位:
Recombinant Plasodium falciparum CelTOS vaccine
-
批准号:7665547
-
项目类别:
-
资助金额:$29.27万
-
财政年份:2008
-
负责人:B. KIM LEE SIM
-
依托单位:
Recombinant Plasodium falciparum CelTOS vaccine
-
批准号:7538903
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:B. KIM LEE SIM
-
依托单位:
Plasmodium vivax recombinant CS protein vaccine for malaria
-
批准号:8243658
-
项目类别:
-
资助金额:$86.3万
-
财政年份:2005
-
负责人:B. KIM LEE SIM
-
依托单位:
海外基金